Regeneron scores $400M+ jury win in Amgen cholesterol drug spat
A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case against Amgen.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
